Janssen Cilag International

Haematologic Malignancies and Blood Disorders

Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.

  • Multiple myeloma and plasma cell disorders
  • B-cell non-Hodgkin lymphoma and CLL/SLL
  • Acute leukemia and myelodysplastic neoplasms

Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.

Oncology in Solid Tumours

The sponsor funds research in non-small cell lung cancer, prostate cancer, urothelial cancer, bladder cancer, colorectal cancer, head and neck squamous cell carcinoma, and other advanced solid tumors, including metastatic and recurrent disease settings.

  • Non-small cell lung cancer
  • Prostate cancer
  • Urothelial and bladder cancers

Additional activity includes studies in gastric cancer, advanced solid tumors, and biomarker-defined tumour populations.

Immune-Mediated and Inflammatory Diseases

Clinical research includes psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and idiopathic inflammatory myopathies, with both adult and paediatric populations represented.

  • Psoriasis and psoriatic arthritis
  • Inflammatory bowel disease
  • Systemic autoimmune and rheumatologic disease

Work also covers atopic dermatitis, asthma, and chronic inflammatory demyelinating polyneuropathy.

Neurology, Psychiatry, and Ophthalmology

Janssen Cilag International supports studies in Alzheimer’s disease, major depressive disorder, bipolar depression, myasthenia gravis, chronic inflammatory neuropathies, and stroke prevention, together with ophthalmic research in geographic atrophy and X-linked retinitis pigmentosa.

  • Alzheimer’s disease and cognitive decline
  • Depression and related mood disorders
  • Neuromuscular and retinal disorders

Further interest includes acute suicidal ideation and healthy volunteer studies supporting neurological and psychiatric development.

Cardiovascular, Maternal, Infectious, and Metabolic Conditions

The portfolio also includes atrial fibrillation, acute coronary syndrome, atherothrombotic and thromboembolic disorders, acute ischemic stroke, and metastatic castration-sensitive prostate cancer with cardiovascular-relevant treatment questions, as well as maternal-fetal conditions such as hemolytic disease of the fetus and newborn and fetal and neonatal alloimmune thrombocytopenia.

  • Atrial fibrillation and ischemic stroke
  • Maternal-fetal haematology
  • Hepatitis B and hepatitis D co-infection

Research activity also includes tuberculosis, renal impairment, and healthy adult participant studies relevant to drug disposition and clinical use.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    3 1 1 1
    Belgium Czechia France Germany Italy The Netherlands +3
  • Study Comparing Erdafitinib with Vinflunine, Docetaxel, or Pembrolizumab for Patients with Advanced Urothelial Cancer and FGFR Gene Changes

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Belgium France Spain
  • Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Austria Belgium Czechia Denmark Finland France +10
  • Study on Guselkumab for Treating Active Psoriatic Arthritis in Patients with Inadequate Response to One Prior Anti-TNF Agent

    Not recruiting

    3 1
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Spain
  • Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

    Not recruiting

    3 1
    Investigated drugs:
    Bulgaria Czechia Denmark Germany Hungary Italy +5
  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    2 1 1
    Belgium France Germany Italy The Netherlands Spain